15 million Johnson & Johnson coronavirus vaccines ruined due to human error

In a statement Johnson & Johnson said a batch of drug substance failed its quality test

The company said quality control identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, and that batch was never advanced to the filling and finishing stages of its manufacturing process.

It is not expected to change President Joe Biden's expectation that the United States will have enough vaccine for all adults in May. In a statement, J&J said it's working with federal authorities to deliver 24 million doses of the vaccine in April.

Johnson & Johnson's COVID-19 vaccine rollout has been slower than expected in the USA, with just 6.8 million doses delivered to states in the first month.

A batch of Johnson & Johnson's COVID-19 vaccine failed quality standards and can't be used, the drug giant said late Wednesday. Emergent declined to comment.

Federal investigators have ruled that the episode was the result of "human error", NYT reports.

In a statement provided to Fox Business, Johnson & Johnson said it expects to deliver its vaccine at a rate of more than one billion doses by the end of 2021.

Pfizer is shipping its doses ahead of schedule, and Moderna is on the verge of winning approval to deliver vials of vaccine packed with up to 15 doses instead of 10, further boosting the nation's stock.

Drugmaker Johnson & Johnson said Wednesday it had found a quality problem at a Baltimore plant helping manufacture its coronavirus vaccine under contract.

A J&J spokesman said earlier Wednesday that the company met the end-of-March goal, but did not respond to questions about whether the Emergent plant in Baltimore had been cleared by FDA. The FDA is investigating the mistake, but the episode has led to a temporary halt of future J&J shot deliveries from the site, according to the newspaper.